12 Biotechs With Binary Events Coming This Year

RBC Capital analyst Adnan Butt recently named 12 biotech stocks with major binary events expected in 2016.

Here’s a breakdown of the full list.

• Aerie Pharmaceuticals Inc AERI: Phase 3 data for Rhopressa and Roclatan
• Aptose Biosciences Inc APTO: Phase 1 data for APTO-253
• ArQule, Inc. ARQL: Phase 3 interim for tivantinib and Phase 1 data/update for ARQ-092 in Proteus syndrome
• Curis, Inc. CRIS: Phase 1 update from CUDC-907, CA-170 and potential additional programs
• Endocyte, Inc. ECTY: Phase 1 data for EC1456 and EC1169
• Intra-Cellular Therapies Inc ITCI: Phase 3 data for ITI-007
• The Medicines Company MDCO: Phase 2 data for MDCO-216 and ALN-PCSsc and Phase 3 data for Caravance
• Oculus Innovative Sciences, Inc. OCLS: Phase 3 data for OTX-DP, regulatory clarity on OTX-TP development and a POC study or partnership for anti-VEGF IHD
• SCYNEXIS Inc SCYX: Phase 1 and Phase 2 data for i.v. and oral SCY-078
• Steadymed Ltd STDY: Acceptance of Trevyent for review
• Synthetic Biologics Inc SYN: Phase 2 data from SYN-010 and possibly SYN-004
• XOMA Corp XOMA: Phase2/proof-of-concept data from XOMA 358 and potentially Phase 3 from gevokizuamb

Related Link: 2 Fast-Growing Marketing Startups You've Never Heard Of

Butt sees “significant upside” for most of these companies in the case of a positive result, but adds that the sell-off following negative results would most likely be temporary in the majority of cases.

Disclosure: the author holds no position in the stocks mentioned.